about
A new high-level gentamicin resistance gene, aph(2'')-Id, in Enterococcus spp.Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicinAcquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infectionsAminoglycoside resistance genes aph(2")-Ib and aac(6')-Im detected together in strains of both Escherichia coli and Enterococcus faecium.Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.Multiplex PCR for detection of aminoglycoside resistance genes in enterococci.Caspofungin exposure-response relationships in adult patients with mucosal or invasive candidiasis.A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.Source of phosphate in the enzymic reaction as a point of distinction among aminoglycoside 2''-phosphotransferases.Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study.In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART).Imipenem resistance associated with the loss of a 40 kDa outer membrane protein in Enterobacter aerogenes.In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).Aminoglycoside 2''-phosphotransferase type IIIa from Enterococcus.In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART).Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.Is pneumonia really the old man's friend? Two-year prognosis after community-acquired pneumonia.Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programmeEnterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapyKinetic mechanism of enterococcal aminoglycoside phosphotransferase 2"-Ib
P50
Q33695820-5C2874E1-40B4-43F7-9850-6CA48AE74F79Q33768781-D05B01DE-D395-46A7-8680-39C820A010DEQ33938132-D8E265B4-1243-420C-88FA-108A6F7C7ACEQ33983032-AAE321FA-B379-44F7-ADC5-FCBE6245B80AQ37115709-129B38C2-CA8B-4276-BE9D-C46FDCD7178EQ39743479-0C2E9C5C-A63C-42C6-92C8-3ACE54F51886Q39810663-14D22215-91AC-487B-B052-3B694CC724C4Q40270089-647E68CD-DFFD-4F41-8E4C-9795D860DD33Q40359965-2C476A2D-1E71-4AF3-B475-D9DB0094EF59Q41776282-A8665594-9738-4CAC-B52F-09ACE9154E8FQ43751593-49D47E80-CDA6-4C7F-B4DD-74908631319EQ43805033-3FF3424C-0268-4432-97B8-7E1B3B573CF5Q43923926-2322AE52-5C10-442E-BA25-3784DBFB46F8Q44007271-BDA7067F-4822-436C-8952-A3B006E76C29Q46804930-027B7245-92C4-4004-BD37-E6C1B98AA59DQ46909108-3C6E4921-F157-40F4-A582-3C0C4456BAECQ47677515-B6967E4D-B1C6-4449-93AE-D1217C240805Q50125381-7C0E240F-54B3-4494-9566-E890A94CB551Q56888416-B47B54B5-14FD-43B8-9852-302A73786853Q67973601-1751FE57-3FA0-464D-8B95-E03688BACFEEQ80138477-87491A9E-E525-4D8B-8772-829B82C14989
P50
description
researcher ORCID ID = 0000-0002-5934-5877
@en
wetenschapper
@nl
name
Joseph W Chow
@ast
Joseph W Chow
@en
Joseph W Chow
@nl
type
label
Joseph W Chow
@ast
Joseph W Chow
@en
Joseph W Chow
@nl
prefLabel
Joseph W Chow
@ast
Joseph W Chow
@en
Joseph W Chow
@nl
P31
P496
0000-0002-5934-5877